Sravan K. Emany serves as the Chief Financial Officer (CFO) at Beam Therapeutics Inc., a biotechnology company focused on developing precision genetic medicines through its proprietary base editing technology. Emany brings a wealth of experience in financial strategy and operations within the life sciences sector to his role at Beam Therapeutics. Prior to joining Beam, he held the position of CFO at Voyager Therapeutics, another innovative biotechnology firm, where he played a pivotal role in steering the company through its initial public offering (IPO) and subsequent growth phases. Before his tenure at Voyager Therapeutics, Emany was the CFO at Kolltan Pharmaceuticals, where he was instrumental in guiding the company through various financing rounds and strategic partnerships. His earlier career also includes significant roles at OSI Pharmaceuticals, where he contributed to the company's financial management and was part of the team during its acquisition by Astellas Pharma. Emany's expertise extends beyond traditional finance, encompassing strategic planning, investor relations, and business development, making him a valuable asset to Beam Therapeutics. As CFO of Beam Therapeutics, Sravan K. Emany is responsible for overseeing the company's financial operations, including budgeting, forecasting, and financial reporting. His strategic vision is crucial in navigating the complex landscape of biotechnology financing, ensuring that Beam Therapeutics has the resources needed to advance its innovative gene-editing therapies from research to clinical application. Under his leadership, the company aims to continue its trajectory of growth and innovation, solidifying its position at the forefront of the genetic medicine revolution.